Vigil Neuroscience (VIGL)

Company Profile

Vigil Neuroscience Vigil Neuroscience is a clinical-stage microglia-focused therapeutics company Our purpose: to treat rare and common neurodegenerative diseases by restoring the vigilance of microglia, the brain’s sentinel immune cells We are utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities as we seek to deliver precision-based therapies to improve the lives of patients and their families © Vigil Neuroscience, Inc. 2023. All rights reserved.

Company profile

Ticker

VIGL

Exchange

Incorporated

Location

Fiscal year end

Sector

Professional, Scientific, and Technical Services > Research and Development in Biotechnology

Industry (SIC)

Biological Products, (No Diagnostic Substances)

AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Exelixis • Sana Biotechnology • Bio-Techne • Ginkgo Bioworks ...

SEC CIK

0001827087

Corporate docs

Underwriting Agreements

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

VIGL stock data

1M 1Y 5Y

Analyst ratings and price targets

Last 3 months

Average target

$15.50

Low target

$12.00

High target

$19.00

Latest filings (excl ownership)

View all

8-K

Regulation FD Disclosure

9 Jan 23

8-K

Vigil Neuroscience Appoints David Gray, Ph.D., as Chief Scientific Officer and Announces Changes to Executive Team

15 Dec 22

8-K

Vigil Neuroscience Announces First Patient Dosed in the IGNITE Phase 2 Clinical Trial to Evaluate VGL101 in Patients with ALSP

14 Dec 22

8-K

Regulation FD Disclosure

10 Nov 22

Vigil Neuroscience Reports Third Quarter 2022 Financial Results and Provides Business Update

10 Nov 22

8-K

Regulation FD Disclosure

2 Nov 22

EFFECT

Notice of effectiveness

17 Oct 22

CORRESP

Correspondence with SEC

Latest ownership filings

View all

SC 13D/A

Northpond Ventures, LP

16 Dec 22

Spyros Papapetropoulos

22 Nov 22

SC 13G

BIOTECHNOLOGY VALUE FUND L P

26 Aug 22

SC 13G

Artal International S.C.A.

23 Aug 22

SC 13G

Deep Track Capital, LP

Financial summary

Financial statements Chart VIGL financial data

Quarter (USD)	Sep 22	Jun 22	Mar 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	204.79 mm	204.79 mm	204.79 mm	204.79 mm	204.79 mm	204.79 mm
Cash burn (monthly)	(no burn)	(no burn)	5.88 mm	4.17 mm	(no burn)	1.51 mm
Cash used (since last report)	n/a	n/a	25.15 mm	17.83 mm	n/a	6.46 mm
Cash remaining	n/a	n/a	179.64 mm	186.96 mm	n/a	198.33 mm
Runway (months of cash)	n/a	n/a	30.6	44.9	n/a	131.4

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2022

VIGL institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	38	37	+2.7%
Opened positions	9	5	+80.0%
Closed positions	8	18	-55.6%
Increased positions	11	6	+83.3%
Reduced positions	4	13	-69.2%

13F shares	Current	Prev Q	Change
Total value	390.70 mm	173.23 mm	+125.5%
Total shares	42.46 mm	28.17 mm	+50.7%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Atlas Venture Life Science Advisors	5.84 mm	$53.12 mm	0.0%
Atlas Venture Fund XII	4.81 mm	$57.03 mm	0.0%
Northpond Ventures	4.21 mm	$38.35 mm	0.0%
AMGN AMGEN	3.21 mm	$38.03 mm	0.0%
Northpond Ventures	2.83 mm	$33.58 mm	0.0%
Biotechnology Value Fund L P	2.74 mm	$21.56 mm	NEW
Deep Track Capital	2.36 mm	$21.51 mm	+666.3%
Artal	2.29 mm	$20.80 mm	+103.9%
Artal International S.C.A.	2.29 mm	$17.99 mm	NEW
Citadel Advisors	2.17 mm	$19.72 mm	+0.1%

Largest transactions	Shares	Bought/sold	Change
Biotechnology Value Fund L P	2.74 mm	+2.74 mm	NEW
Artal International S.C.A.	2.29 mm	+2.29 mm	NEW
Deep Track Capital	2.36 mm	+2.05 mm	+666.3%
Deerfield Management	2.05 mm	+2.05 mm	NEW
Flynn James E	2.05 mm	+2.05 mm	NEW
BVF	1.81 mm	+1.81 mm	NEW
Artal	2.29 mm	+1.16 mm	+103.9%
DAFNA Capital Management	216.40 k	+116.64 k	+116.9%
Renaissance Technologies	0.00	-37.49 k	EXIT
Ergoteles	28.53 k	+28.53 k	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

VIGL insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
18 Nov 22	Spyridon Papapetropoulos	Common Stock	Sell	Dispose S	No	Yes	14	300	4.20 k	4,000
18 Nov 22	Spyridon Papapetropoulos	Common Stock	Option exercise	Acquire M	No	No	1.89	300	567.00	4,300
18 Nov 22	Spyridon Papapetropoulos	Stock Option Grant Common Stock	Option exercise	Dispose M	No	No	1.89	300	567.00	149,604
27 Jul 22	Bruhn Suzanne Louise	Stock Option Grant Common Stock	Grant	Acquire A	No	No	6.93	24,310	168.47 k	24,310
9 Jun 22	Stefan Vitorovic	Stock Option Grant Common Stock	Grant	Acquire A	No	No	3.1	12,155	37.68 k	12,155
9 Jun 22	Gerhard Koenig	Stock Option Grant Common Stock	Grant	Acquire A	No	No	3.1	12,155	37.68 k	12,155